10 completed, 6 terminated, 3 recruiting, 2 withdrawn. 15 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 8, Terminated 3, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 12 | Completed 6, Terminated 4, Recruiting 1, Withdrawn 1 |
Follow Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive: new trials by email Literature Review of Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials Research Report on Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia Decitabine, Ponatinib, Venetoclax - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2020-05-17 | 2026-06-05 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Rivogenlecleucel, Rimiducid - Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2020-01-02 | 2020-08-14 | |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy Edetate Calcium Disodium, Multivitamin, Succimer - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 58 | 2018-10-11 | 2026-09-18 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 204 | 2016-08-05 | 2026-08-06 |
| Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia Pioglitazone, Tyrosine Kinase Inhibitor (TKI) - Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Terminated | Emory University | 9 | 2016-05-01 | 2019-01-09 |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil - Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome | Phase 1 | Terminated | Stanford University | 1 | 2016-02-01 | 2018-09-12 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Bosutinib, Inotuzumab Ozogamicin - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2015-04-16 | 2023-07-17 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 84 | 2015-03-23 | 2026-06-01 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Cladribine, Cytarabine, Gilteritinib - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 508 | 2014-05-19 | 2026-05-20 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 54 | 2014-04-22 | 2024-01-24 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 63 | 2013-06-11 | 2023-11-07 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 71 | 2013-05-16 | 2021-06-24 |
| Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment - Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2013-01-17 | 2026-09-16 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate - Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Phase 2 | Completed | Fred Hutchinson Cancer Center | 47 | 2012-09-25 | 2020-01-02 |
Showing 20 of 22. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (22) · Leukemia, Myeloid, Acute (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Blast Crisis (12) · Hodgkin Disease (10) · Myelodysplastic Syndromes (9) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Multiple Myeloma (7) · Leukemia, Myeloid, Accelerated Phase (6) · Lymphoma, Non-Hodgkin (6) · Myelodysplastic-Myeloproliferative Diseases (6) · Blastic Plasmacytoid Dendritic Cell Neoplasm (5) · Hematologic Neoplasms (5) · Leukemia, Biphenotypic, Acute (5) · Myeloproliferative Disorders (5)
Bone Marrow Diseases (22) · Chronic Disease (22) · Disease Attributes (22) · Hemic and Lymphatic Diseases (22) · Leukemia (22) · Leukemia, Myeloid (22) · Neoplasms (22) · Neoplasms by Histologic Type (22) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Hematologic Diseases (21) · Myeloproliferative Disorders (17) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Leukemia, Lymphoid (15)
Mycophenolic Acid (8) · fludarabine phosphate (6) · Cyclophosphamide (5) · Peripheral Blood Stem Cell Transplantation (5) · Tacrolimus (5) · Whole-Body Irradiation (5) · Sirolimus (4) · ponatinib (4) · venetoclax (4) · fludarabine (3) · Busulfan (2) · CTLA-4 Antigen (2) · Calcium Dobesilate (2) · Cyclosporine (2) · Cyclosporins (2)
M.D. Anderson Cancer Center (10) · Fred Hutchinson Cancer Center (6) · City of Hope Medical Center (2) · Emory University (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Stanford University (1)
United States (21) · Denmark (1) · Germany (1)
Brenda Sandmaier (2) · Tapan M Kadia (2) · Elias Jabbour, MD (1) · Elizabeth Krakow (1) · Farhad Ravandi-Kashani (1) · Ibrahim Aldoss, MD (1) · Ibrahim T Aldoss (1) · Lara Davis, MD (1) · Marco Mielcarek (1) · Marie Bleakley (1) · Maro Ohanian (1) · Masumi Ueda Oshima (1) · Matthew S Davids (1) · Nicholas Short (1) · Nitin Jain (1)
PMID 32499241, PMID 25085357, PMID 27410923, PMID 29702001, PMID 32478814, PMID 33720354, PMID 34312462, PMID 34329576, PMID 35007144, PMID 35622074, PMID 37611156, PMID 39303729, PMID 39863139, PMID 40193193, PMID 40500616, PMID 41043099
P30CA015704 (5), P01CA018029 (3), P01CA078902 (2), P01CA049639 (1), P30CA006516 (1), P30CA033572 (1), R01CA183559 (1), R01HL121568 (1), U01CA062490 (1), UM1CA186709 (1)